Short Interest in BioTime, Inc. (BTX) Expands By 3.9%
BioTime, Inc. (NYSEAMERICAN:BTX) was the target of a significant growth in short interest in the month of September. As of September 14th, there was short interest totalling 13,666,548 shares, a growth of 3.9% from the August 31st total of 13,153,727 shares. Based on an average daily volume of 505,083 shares, the short-interest ratio is currently 27.1 days. Approximately 10.9% of the company’s shares are sold short.
NYSEAMERICAN BTX opened at $2.37 on Thursday. BioTime has a twelve month low of $1.98 and a twelve month high of $3.16.
BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.03. The business had revenue of $2.55 million during the quarter, compared to the consensus estimate of $0.33 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%.
A number of hedge funds and other institutional investors have recently bought and sold shares of BTX. Schwab Charles Investment Management Inc. increased its holdings in BioTime by 20.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 173,856 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 30,056 shares during the period. Northern Trust Corp increased its holdings in BioTime by 5.2% in the first quarter. Northern Trust Corp now owns 966,448 shares of the biotechnology company’s stock valued at $2,600,000 after purchasing an additional 47,957 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in BioTime by 4.7% in the second quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock valued at $1,534,000 after purchasing an additional 33,350 shares during the period.
BioTime Company Profile
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.